New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
09:22 EDTSTJSt. Jude Medical warning letter not clearing event, says Citigroup
Citigroup believes the next FDA action regarding St. Jude Medical's Sylmar is likely to be a threat of injunction that normally leads to a consent decree. Further, Citi believes the FDA will ultimately have to make a determination on the safety of Durata, with the firm still believing a recall is likely. Citi says the FDA's Sylmar Warning Letter is not a clearing event, but the next step in a process that looks ominous for St. Jude. The firm keeps a Sell rating on the stock with a $32 price target.
News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
09:08 EDTSTJSt. Jude Medical well-positioned heading into 2015, says Wedbush
Subscribe for More Information
08:53 EDTSTJSt. Jude Medical weakness a buying opportunity, says CRT Capital
CRT Capital would use St. Jude Medical weakness as a buying opportunity based on accelerating EPS growth and expects CardioMEMS to be a $1B revenue opportunity over the next few years. Shares are Buy rated with a $80 price target.
07:45 EDTSTJSt. Jude Medical price target lowered to $66 from $75 at Stifel
Subscribe for More Information
October 15, 2014
08:37 EDTSTJSt. Jude Medical expects AF products revenue to accelerate in FY15
As the company look to FY15, aims to continue to accelerate its sales growth rate. Expects the acceleration to come from its men's heart failure monitor system and chronic pain business. Expects to grow sales faster in FY15 compared to FY14.
08:32 EDTSTJSt. Jude Medical sees YOY currency impact on sales $50M-$60M for Q4
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical reports Q3 total CRM sales $688M
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical narrows FY14 adjusted EPS view to $3.97-$3.99 from $3.96-$4.01
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical sees Q4 adjusted EPS $1.02-$1.04, consensus $1.04
Subscribe for More Information
07:32 EDTSTJSt. Jude Medical Sees FY14 adjusted EPS $3.97-$3.99, consensus $3.98
Sees FY14 revenue $5.586B-$5.648B, consensus $5.69B.
07:31 EDTSTJSt. Jude Medical reports Q3 adjusted EPS 97c, consensus 96c
Reports Q3 revenue $1.37B, consensus $1.38B.
October 14, 2014
15:29 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
October 13, 2014
07:25 EDTSTJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use